Genmab — Juli 2020
-
Indtil videre er det kun NSCLC med Exon 19 mutationen forsøgene går efter. Jeg mener, at det er 15-20% af hele NSCLC populationen - herunder first line. https://mc.vanderbilt.edu/ckm/gl/mutation_profiles/pdfopen.php?fnp=lung_cancer/content/EGFR/Lung_Cancer_and_EGFR_Exon_19_Deletions.pdf
-
Tak for svar til Solsen og Bulder
-
About 20 percent of NSCLC cases have somatic EGFR mutations. (15) Patients with the two most common mutations, EGFR L858R and EGFR exon deletion 19, are treated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs), which include erlotinib, gefitinib, afatinib, dacomitinib, and osimertinib. https://www.mskcc.org/clinical-updates/systemic-therapy-locally-advanced-and-metastatic-non-small-cell-lung
-
Amgen dumps early-stage CD38xCD3 bispecific, returning rights to Xencor https://endpts.com/amgen-dumps-early-stage-cd38xcd3-bispecific-returning-rights-to-xencor-picked-up-in-2015-alliance/
-
"World bispecific" har conference sidst i september og så vidt jeg kan se er Genmabs fravær påfaldende. Ydermere er der dagen op til en dag med særlig fokus på CD3 bispecifics https://bispecific.com/whats-on/agenda-at-a-glance/
-
On the Amivantamab trial note that the purpose is two-fold: In one part Lazertinib (arm C) is compared to Osimertinib (arm B), this part is blinded. In the other part Amivantamab is tested as add-on to Lazertinib (arm A) this part is open label, so JnJ can follow during the trial if this combo outperforms the blinded part, which is what we hope for
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind